Relmada Therapeutics Inc. Switches Audit Firms Amid Acquisition, No Disagreements Reported

Reuters

05-13

Relmada <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Switches Audit Firms Amid Acquisition, No Disagreements Reported

Relmada Therapeutics Inc. has announced a change in its certifying accountants following the acquisition of Marcum LLP's attest business by CBIZ CPAs P.C. As a result of this acquisition, Relmada has dismissed Marcum as its independent registered public accounting firm, effective May 8, 2025, with the approval of the company's audit committee. Marcum's audit reports for fiscal years 2023 and 2024 did not contain adverse or qualified opinions, except for an explanatory note on the company's ability to continue as a going concern. Subsequently, CBIZ CPAs has been engaged as the new independent registered public accounting firm for the fiscal year ending December 31, 2025. The company noted that during the fiscal years 2023 and 2024, there were no disagreements or reportable events with Marcum concerning accounting principles, practices, or financial disclosures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-042024), on May 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535789769"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535789769\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535789769?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 04:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535789769","market":"nz","top_or_hot":-1,"title":"Relmada Therapeutics Inc. Switches Audit Firms Amid Acquisition, No Disagreements Reported","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Switches Audit Firms Amid Acquisition, No Disagreements Reported\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relmada Therapeutics Inc. has announced a change in its certifying accountants following the acquisition of Marcum LLP's attest business by CBIZ CPAs P.C. As a result of this acquisition, Relmada has dismissed Marcum as its independent registered public accounting firm, effective May 8, 2025, with the approval of the company's audit committee. Marcum's audit reports for fiscal years 2023 and 2024 did not contain adverse or qualified opinions, except for an explanatory note on the company's ability to continue as a going concern. Subsequently, CBIZ CPAs has been engaged as the new independent registered public accounting firm for the fiscal year ending December 31, 2025. The company noted that during the fiscal years 2023 and 2024, there were no disagreements or reportable events with Marcum concerning accounting principles, practices, or financial disclosures.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-042024), on May 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relmada Therapeutics Inc. Switches Audit Firms Amid Acquisition, No Disagreements Reported</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelmada Therapeutics Inc. Switches Audit Firms Amid Acquisition, No Disagreements Reported\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-13 04:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Switches Audit Firms Amid Acquisition, No Disagreements Reported\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relmada Therapeutics Inc. has announced a change in its certifying accountants following the acquisition of Marcum LLP's attest business by CBIZ CPAs P.C. As a result of this acquisition, Relmada has dismissed Marcum as its independent registered public accounting firm, effective May 8, 2025, with the approval of the company's audit committee. Marcum's audit reports for fiscal years 2023 and 2024 did not contain adverse or qualified opinions, except for an explanatory note on the company's ability to continue as a going concern. Subsequently, CBIZ CPAs has been engaged as the new independent registered public accounting firm for the fiscal year ending December 31, 2025. The company noted that during the fiscal years 2023 and 2024, there were no disagreements or reportable events with Marcum concerning accounting principles, practices, or financial disclosures.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-042024), on May 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLMD","symbol_name":"Relmada Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nNDL8THyyQ:1","article_id":"2535789769","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535789769","pubTimestamp":1747080430,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Relmada Therapeutics Inc. has announced a change in its certifying accountants following the acquisition of Marcum LLP's attest business by CBIZ CPAs P.C. As a result of this acquisition, Relmada has dismissed Marcum as its independent registered public accounting firm, effective May 8, 2025, with the approval of the company's audit committee. Marcum's audit reports for fiscal years 2023 and 2024 did not contain adverse or qualified opinions, except for an explanatory note on the company's ability to continue as a going concern. Subsequently, CBIZ CPAs has been engaged as the new independent registered public accounting firm for the fiscal year ending December 31, 2025. The company noted that during the fiscal years 2023 and 2024, there were no disagreements or reportable events with Marcum concerning accounting principles, practices, or financial disclosures.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLMD":"Relmada Therapeutics, Inc.","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","CBZ":"CBIZ Inc","BK4007":"制药","BK4123":"调查和咨询服务"},"translate_title":"Relmada Therapeutics Inc.在收购过程中更换审计公司，未报告存在分歧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CBZ":0.9,"RLMD":0.9},"content_text":"Relmada Therapeutics Inc. Switches Audit Firms Amid Acquisition, No Disagreements Reported\n    \n\n        Relmada Therapeutics Inc. has announced a change in its certifying accountants following the acquisition of Marcum LLP's attest business by CBIZ CPAs P.C. As a result of this acquisition, Relmada has dismissed Marcum as its independent registered public accounting firm, effective May 8, 2025, with the approval of the company's audit committee. Marcum's audit reports for fiscal years 2023 and 2024 did not contain adverse or qualified opinions, except for an explanatory note on the company's ability to continue as a going concern. Subsequently, CBIZ CPAs has been engaged as the new independent registered public accounting firm for the fiscal year ending December 31, 2025. The company noted that during the fiscal years 2023 and 2024, there were no disagreements or reportable events with Marcum concerning accounting principles, practices, or financial disclosures.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-042024), on May 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"merge,event","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}